Rivaroxaban with or without Aspirin in Stable Cardiovascular Disease
| Autor: | Stephane Ederhy, Gilmar Reis, Andrzej Rynkiewicz, Keith Fox, Luca Padua, Helene ABERGEL, Andrew Murphy, Andrzej Szuba, YAN CARLOS DUARTE VERA, Pawel Maga, Scott Berkowitz, Roxana Buzas, Alexey Repin, Gregory Ducrocq, Olga Barbarash, Anton Sadomov, Grzegorz Gajos, Miguel Urina, David McEneaney, Richard Tytus, Dmitriy Panov, Angelika Chachaj, Weimar Kunz Sebba Barroso Souza, Akihiko Takahashi, Salim Yusuf, Mpiko Ntsekhe, Elena Gromova, David Halon, Richard Cheng, Marcello Galvani, Rohan Poulter, JUAN PABLO YEPEZ ALVARAN, Sara Doimo, Kim Houlind, Marcelo Arruda Nakazone, Avinainder Singh, Fabrice Martens, Aldo Pietro Maggioni, Fredrik Folke, Miroslav Brtko, Peter Verhamme, Laszlo Koranyi, Bart Meuris, ALVARO AVEZUM, Boris Vesga, Cyrille Boulogne, Peter Sinnaeve, Zhanna Sizova, Marianna Janion, Crina Julieta Sinescu, Laurent BERTOLETTI, Susanne Brenner, Jaroslav Hlubocký, ELENA BOBESCU, Michelle Canavan, Kamil Bury, Elena Nalesnik, Robert Mikulik, Yaroslav Malynovsky, Liudmyla Parkhomenko, Andrea Barbieri, Philippe Gabriel STEG, Kelley Branch, Olga Shestakovska, Jan Fedacko, Khairul Shafiq Ibrahim, Nicolae-Dan Tesloianu, Daniel Pella, Paul Fedak, Pavel Kaplan, Shirley Jansen, Martin O'Donnell, Marlena Broncel, Fernando Lanas, Stefan Störk, Natalia Garganeeva, Heyman Luckraz, CARLOS AUGUSTO CELEMIN FLOREZ, Larysa Mishchenko, Amos Katz, Jaroslava Paulasova Schwabova, Patricio Lopez-Jaramillo, Gustavo Aroca, Monika Możdżan, Zoltan Varallyay, María José Paucar, Tim Ramsay, Fernando Botto, Muhammad Imran Abdul Hafidz, Juan Esteban Gómez-Mesa, Kaijian Hou, Miroslav Spacek, Tomasz Guzik, Diego Rizzotti, Jackie Bosch, Shrikant Bangdiwala, Robert Welsh, Vojtěch Novotný, Andriy Bazylevych, Niall Mahon, Serhii Serik, Irina PARVU, Daniel Turek, Laurent Feldman, Dmitry Zateyshchikov, Mykola Bychkov, Yury Vasyuk, Camilo Felix, James Cotton, DHAYRA KAREM BARRETO, Sergey Kozhukhov, Sergio Zimmermann, Whady Hueb |
|---|---|
| Přispěvatelé: | AP-HP - Hôpital Bichat - Claude Bernard [Paris], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP), Université Paris Diderot - Paris 7 (UPD7), Biomedical Engineering and Physics, Other departments, ACS - Amsterdam Cardiovascular Sciences, Pulmonology, Graduate School, Radiology and Nuclear Medicine, AGEM - Amsterdam Gastroenterology Endocrinology Metabolism |
| Rok vydání: | 2017 |
| Předmět: |
Male
030204 cardiovascular system & hematology law.invention 0302 clinical medicine Rivaroxaban Randomized controlled trial law Hemorrhage/chemically induced Secondary Prevention Atherosclerosis/complications 030212 general & internal medicine Myocardial infarction Factor Xa Inhibitors/adverse effects Rivaroxaban/adverse effects Stroke risk Aspirin oral rivaroxaban Research Support Non-U.S. Gov't Hazard ratio General Medicine Middle Aged trial Clopidogrel 3. Good health Multicenter Study Cardiovascular Diseases Randomized Controlled Trial Platelet aggregation inhibitor Drug Therapy Combination Female secondary prevention medicine.drug Platelet Aggregation Inhibitors/adverse effects medicine.medical_specialty venous thromboembolism Hemorrhage Aspirin/adverse effects 03 medical and health sciences Secondary Prevention/methods Double-Blind Method Internal medicine Journal Article medicine Humans Aged clopidogrel business.industry ta3121 Atherosclerosis atherothrombotic events medicine.disease Surgery Cardiovascular Diseases/drug therapy business Platelet Aggregation Inhibitors [SDV.MHEP]Life Sciences [q-bio]/Human health and pathology Factor Xa Inhibitors |
| Zdroj: | Eikelboom, J W, Connolly, S J, Bosch, J, Dagenais, G R, Hart, R G, Shestakovska, O, Diaz, R, Alings, M, Lonn, E M, Anand, S S, Widimsky, P, Hori, M, Avezum, A, Piegas, L S, Branch, K R H, Probstfield, J, Bhatt, D L, Zhu, J, Liang, Y, Maggioni, A P, Lopez-Jaramillo, P, O'Donnell, M, Kakkar, A, Fox, K A A, Parkhomenko, A N, Ertl, G, Störk, S, Keltai, M, Ryden, L, Pogosova, N, Dans, A L, Lanas, F, Commerford, P J, Torp-Pedersen, C, Guzik, T J, Verhamme, P B, Vinereanu, D, Kim, J-H, Tonkin, A M, Lewis, B S, Felix, C, Yusoff, K, Steg, P G, Metsarinne, K P, Cook Bruns, N, Misselwitz, F, Chen, E, Leong, D, Yusuf, S & COMPASS Investigators 2017, ' Rivaroxaban with or without aspirin in stable cardiovascular disease ', New England Journal of Medicine, vol. 377, no. 14, pp. 1319-1330 . https://doi.org/10.1056/NEJMoa1709118 New England Journal of Medicine New England Journal of Medicine, Massachusetts Medical Society, 2017, 377 (14), pp.1319-1330. ⟨10.1056/NEJMoa1709118⟩ Eikelboom, J W, Connolly, S J, Bosch, J, Dagenais, G R, Hart, R G, Shestakovska, O, Diaz, R, Alings, M, Lonn, E M, Anand, S S, Widimsky, P, Hori, M, Avezum, A, Piegas, L S, Branch, K R H, Probstfield, J, Bhatt, D L, Zhu, J, Liang, Y, Maggioni, A P, Lopez-Jaramillo, P, O'Donnell, M, Kakkar, A K, Fox, K A A, Parkhomenko, A N, Ertl, G, Störk, S, Keltai, M, Ryden, L, Pogosova, N, Dans, A L, Lanas, F, Commerford, P J, Torp-Pedersen, C, Guzik, T J, Verhamme, P B, Vinereanu, D, Kim, J-H, Tonkin, A M, Lewis, B S, Felix, C, Yusoff, K, Steg, P G, Metsarinne, K P, Cook Bruns, N, Misselwitz, F, Chen, E, Leong, D, Yusuf, S, COMPASS Investigators & Houlind, K C 2017, ' Rivaroxaban with or without Aspirin in Stable Cardiovascular Disease ', The New England Journal of Medicine, vol. 377, no. 14, pp. 1319-1330 . https://doi.org/10.1056/NEJMoa1709118 New England journal of medicine, 377(14), 1319-1330. Massachussetts Medical Society COMPASS Investigators 2017, ' Rivaroxaban with or without Aspirin in Stable Cardiovascular Disease ', The New England Journal of Medicine, vol. 377, no. 14, pp. 1319-1330 . https://doi.org/10.1056/NEJMoa1709118 |
| ISSN: | 1533-4406 0028-4793 |
| Popis: | BACKGROUND: We evaluated whether rivaroxaban alone or in combination with aspirin would be more effective than aspirin alone for secondary cardiovascular prevention.METHODS: In this double-blind trial, we randomly assigned 27,395 participants with stable atherosclerotic vascular disease to receive rivaroxaban (2.5 mg twice daily) plus aspirin (100 mg once daily), rivaroxaban (5 mg twice daily), or aspirin (100 mg once daily). The primary outcome was a composite of cardiovascular death, stroke, or myocardial infarction. The study was stopped for superiority of the rivaroxaban-plus-aspirin group after a mean follow-up of 23 months.RESULTS: The primary outcome occurred in fewer patients in the rivaroxaban-plus-aspirin group than in the aspirin-alone group (379 patients [4.1%] vs. 496 patients [5.4%]; hazard ratio, 0.76; 95% confidence interval [CI], 0.66 to 0.86; PCONCLUSIONS: Among patients with stable atherosclerotic vascular disease, those assigned to rivaroxaban (2.5 mg twice daily) plus aspirin had better cardiovascular outcomes and more major bleeding events than those assigned to aspirin alone. Rivaroxaban (5 mg twice daily) alone did not result in better cardiovascular outcomes than aspirin alone and resulted in more major bleeding events. (Funded by Bayer; COMPASS ClinicalTrials.gov number, NCT01776424 .). |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|